Related Experiment Video
Updated: Feb 22, 2026
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
Published on: September 25, 2017
Antihypertensive Therapies and Left Ventricular Hypertrophy
Elsayed Z Soliman1,2, Ronald J Prineas3
1Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA. esoliman@wakehealth.edu.
Insights
Lowering blood pressure (BP) effectively helps reverse left ventricular hypertrophy (LVH). Intensive BP reduction shows greater LVH regression than standard treatment, regardless of specific antihypertensive drugs used.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- Left ventricular hypertrophy (LVH) is a common consequence of hypertension.
- Successful blood pressure (BP) lowering is generally accepted to cause LVH regression.
- Debate exists regarding differential effects of various antihypertensive therapies on LVH regression.
Purpose of the Study:
- To review recent literature on the impact of different antihypertensive therapies on LVH regression.
- To analyze the position of current practice guidelines regarding these differences.
- To evaluate the role of intensive BP lowering strategies in LVH regression.
Main Methods:
- Literature review of studies comparing antihypertensive classes and BP-lowering strategies.
- Analysis of current clinical practice guidelines.
- Synthesis of findings on LVH regression in hypertensive patients.
Main Results:
- Studies show inconsistent conclusions regarding specific antihypertensive classes' effects on LVH regression.
- Current guidelines emphasize BP control over specific drug classes, though some mention specific agents.
- Intensive BP lowering (systolic BP < 120 mmHg) consistently demonstrates greater LVH regression than standard targets (> 140 mmHg).
Conclusions:
- Effective BP lowering is the primary driver of LVH regression in hypertension.
- Intensive BP lowering strategies yield superior LVH regression compared to standard approaches.
- Further guideline discussion is warranted regarding intensive BP targets for LVH regression.
Purpose Of Review:
It is widely accepted that successful lowering of blood pressure (BP) in patients with hypertension leads to regression of left ventricular hypertrophy (LVH). However, whether differences exist among pharmacological BP-lowering therapies is debated. In this report, we discuss these differences in light of recent literature and the position of extant practice guidelines.
Recent Findings:
Studies comparing the effects of antihypertensive classes on LVH regression reached different conclusions, but the overall direction which is reflected in current society guidelines is that successful lowering of BP is more important than selection of an individual antihypertensive class. Nevertheless, some practice guidelines added statements about considering a specific antihypertensive class for its potential benefit such as angiotensin-converting enzyme inhibitors and/or excluding a class such as direct vasodilators. On the other hand, reports have been consistent about the more favorable effect of intensive BP-lowering strategy (target systolic BP < 120 mmHg) compared to standard BP lowering (target systolic BP > 140 mmHg), which is not yet discussed in the current practice guidelines. Successful lowering of BP leads to LVH regression. While reports have been inconsistent about differences among antihypertensive classes, lowering BP beyond currently recommended levels has consistently showed a greater effect on LVH regression.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:29Heart Failure II: Pathophysiology
01:22Heart Failure Drugs: Diuretics
01:29Cardiomyopathy V: Interprofessional Care